A Unified Approach to Simultaneous Testing of Superiority and Non-inferiority on Multiple Endpoints in Clinical Trials

Wenfeng Chen¹, Naiqing Zhao², Guoyou Qin², and Jie Chen³*

²Biostatistics and Statistical Programming Merck Serono (Beijing) Pharmaceutical R & D Co., Beijing 100022, China

> ³Department of Biostatistics, School of Public Health Fudan University, Shanghai, 200032, China

³Data Science and Pharmacovigilance, ECR Global Shanghai, China

September 29, 2023

^{*}Correspondence to: Jie Chen, ECR Global, E-Mail: jiechen0713@gmail.com

Abstract

Simultaneous tests of superiority and non-inferiority hypotheses on multiple endpoints are often performed in clinical trials to demonstrate that a new treatment is superior over a control on at least one endpoint and non-inferior on the remaining endpoints. Existing methods tackle this problem by testing the superiority and noninferiority hypotheses separately and control the Type I error rate each at α level. In this paper we propose a unified approach to testing the superiority and non-inferiority hypotheses simultaneously. The proposed approach is based on the UI-IU test and the least favorable configurations of the combined superiority and non-inferiority hypotheses, which leads to the solution of an adjusted significance level α' for marginal tests that controls the overall Type I error rate at pre-defined α . Simulations show that the proposed approach maintains a higher power than existing methods in the settings under investigation. Since the adjusted significance level α' is obtained by controlling the Type I error rate at α , one can easily construct the exact $(1 - \alpha)$ % simultaneous confidence intervals for treatment effects on all endpoints. The proposed approach is illustrated with two real examples.

Key words: Superiority and non-inferiority; union-intersection principle; intersectionunion principle; exact simultaneous confidence intervals; correlated multiple endpoints.

1 Introduction

Clinical trials often use multiple endpoints to capture various therapeutical benefits of an investigational product over a (active) control. For instance, randomized trials conducted in patients with Alzheimer's disease usually employ Alzheimer's disease assessment scalecognitive subpart (ADAS-Cog) and clinical interview-based impression of change (CIBIC-Plus) as measures of treatment effects of a drug (Vellas et al., 2008), and asthmatic studies commonly use forced expiratory volume in one second (FEV₁), peak expiratory flow rate (PEFR), symptoms score (SS, in 0-6 scale) and additional medication use (AMU) (e.g., β agonist) to indicate disease progression or improvement as a result of medical treatment (Zhang et al., 1997; FDA, 2016). As a generic example, a clinical trial may use both efficacy and safety as bivariate endpoints with one endpoint showing superiority and the other noninferiority in order to reach a positive conclusion and thereby gain a regulatory approval. A trial is concluded to be positive or successful if the new treatment is shown to be superior over the control on at least one endpoint and non-inferior on the remaining endpoints via a multiple testing procedure that controls the Type I error probability.

Several methods have been proposed for testing superiority and non-inferiority of multiple endpoints in clinical trials. Bloch et al. (2001) introduce a bootstrap-based approach to multiple-endpoint (one-sided) testing that incorporates univariate and multivariate treatment effects. A non-parametric version of Bloch et al. (2001) is developed by Bloch et al. (2007) to demonstrate that the new treatment is non-inferior to the control for all endpoints using marginal comparisons, and is superior to the control for some endpoints using a global comparison. Bloch et al. (2007) point out that their proposed bootstrap method not only handles the complexity of the null hypotheses and their associated test statistics, but also incorporates various dependence in the multivariate distributions of treatment effects (endpoints). Perlman and Wu (2004) replace the classical Hotelling T^2 test in Bloch et al. (2001) with the likelihood ratio test that utilizes the appropriate multivariate one-sided test. Tamhane and Logan (2004) develop a method that is based on the union-intersection (UI) principle of Roy (1953) for testing superiority on some endpoints and the intersectionunion (IU) principle of Berger (1982) for testing non-inferiority on all endpoints and thereby refer this method as the UI-IU test. They recognize that the critical values for IU tests of non-inferiority may not be further reduced, the constants for UI tests of superiority can be sharpened based on least-favorable configuration of the null hypotheses for superiority. Tamhane and Logan (2004) point out that the UI-IU test is conservative because it requires the Type I error to be controlled separately when testing superiority and non-inferiority of multiple endpoints. Röhmel et al. (2006) argue that it is unacceptable that different choices of non-inferiority margins may impact the conclusion of superiority test and hence propose for a bivariate-endpoint case a three-step procedure in which non-inferiority for both endpoints is tested in the first step, then superiority is tested using a bivariate test (e.g., Holm (1979) or Hochberg (1988)) or Läuter (1996)'s one-sided standard sum (SS) test in the second step, and finally superiority is tested on each endpoint using univariate test in the third step.

As discussed above, all the proposed statistical methods test the superiority and noninferiority hypotheses separately, each at pre-defined significance level α , which does not fully utilize the information on the relationship of test statistics including their dependence structure and superiority and non-inferiority margins. In this paper, we develop a unified approach to simultaneously testing the null hypotheses of superiority and non-inferiority. Specifically, we formulate the problem based on Tamhane and Logan (2004)'s UI-IU test and use the least favorable configurations of the combined null hypotheses of superiority and non-inferiority, which provides the basis for determination of the upper bound of the overall Type I error rate that depends on not only the least favorable configurations of the null hypotheses and the correlation of corresponding test statistics, but also the combined standardized superiority and non-inferiority margins of individual endpoints. Regarding the correlation among endpoints, we can either plug in the estimated partial correlation coefficients, possibly unequal, or use Armitage and Parmar (1986)'s method to approximate the mean partial correlation coefficient which simplifies the computation of critical values for the test statistics.

The rest of the paper is organized as follows. Section 2 describes the problem, preliminaries and notations for testing superiority and non-inferiority hypotheses. In section 3 we present a unified approach to simultaneous testing of superiority and non-inferiority with a focus on the control of overall Type I error rate and the determination of critical values. Simulation results are given in Section 5 to compare our approach to existing methods in terms of Type I error rate control and power. Two examples are presented in Section 6 to illustrate the proposed approach. Finally, some discussions and concluding remarks are given in Section 7.

2 Preliminaries and Notations

Consider a two-arm, randomized clinical trial comparing a treatment with a control on $m \ge 2$ endpoints. The objective is to demonstrate superiority of the treatment over the control on at least one endpoint and non-inferiority on the remaining endpoints. Following the notations in Tamhane and Logan (2004), let $\mathbf{X}_{ij} = \{X_{ijk} : k = 1, ..., m\}$ be a vector of response variables from the *j*th subject in the *i*th group, i = 1, 2 and $j = 1, ..., n_i$. Suppose that \mathbf{X}_{ij} are independent and identically distributed from an *m*-variate normal distribution with mean vectors $\boldsymbol{\mu}_i = \{\mu_{i\cdot k} : k = 1, ..., m\}$ and a common unknown variance-covariance matrix $\boldsymbol{\Sigma} = \{\rho_{k_1k_2}\sigma_{k_1}\sigma_{k_2}\}, 1 \le k_1 \le k_2 \le m$. Let $\boldsymbol{\Theta} = \{\theta_k : k = 1, ..., m\}$ with $\theta_k = \mu_{1\cdot k} - \mu_{2\cdot k}$ being the mean difference in the *k*th endpoint between the two groups. The treatment is considered superior over the control if $\theta_k \ge \epsilon_k$ or non-inferior to the control if

 $\theta_k \ge -\eta_k$ in the *k*th endpoint, where $\epsilon_k \ge 0$ and $\eta_k \ge 0$ are suitably pre-defined respective superiority and non-inferiority margins for the *k*th endpoint.

Let's define the null hypothesis of superiority $H_{0k}^{S}: \theta_{k} \leq \epsilon_{k}$ and its alternative hypothesis $H_{1k}^{S}: \theta_{k} > \epsilon_{k}$, and the null hypothesis of non-inferiority $H_{0k}^{NI}: \theta_{k} \leq -\eta_{k}$ and the corresponding alternative hypothesis $H_{1k}^{NI}: \theta_{k} > -\eta_{k}$ for the *k*th endpoint, k = 1, ..., m. Let $H_{0}^{S}: \bigcap_{k=1}^{m} H_{0k}^{S}$ and $H_{0}^{NI}: \bigcup_{k=1}^{m} H_{1k}^{NI}$, then $H^{S} = \bigcup_{k=1}^{m} H_{k=1}^{S}$ and $H^{NI}: \bigcap_{k=1}^{m} H_{k=1}^{NI}$ here objective of the trial can be formulated as testing the null hypothesis

$$H_0: H_0^S \cup H_0^N$$

against the alternative hypothesis

$$H_1: H_1^S \cap H_1^{NI}$$
,

which is termed as UI-IU test in Tamhane and Logan (2004). Let $\bar{X}_{i:k} = \frac{1}{n_i} \sum_{j=1}^{n_i} X_{ijk}$ be the sample mean of the *k*th endpoint for the *i*th group, i = 1, 2, and

$$T_{k} = \frac{\bar{X}_{1\cdot k} - \bar{X}_{2\cdot k} - \theta_{k}}{\hat{\sigma}_{k} \quad \overline{1/n_{1} + 1/n_{2}}},$$
(1)

with $\hat{\sigma}_k$ being an estimate of σ_k . Each of the T_k 's marginally follows a univariate *t*-distribution with $d = m(n_1+n_2-2)$ degrees of freedom, denoted by t_d , and $\mathbf{T} = (T_1, \ldots, T_m)$ follows an *m*-variate *t*-distribution with degrees of freedom *d* and partial correlation coefficients $\rho_{k_1k_2}$.

To test $H^{S}_{0k} \theta_{k} \leq \epsilon_{k}$ against $H^{S} : \theta_{fk} \geq \epsilon_{k}$, one simply constructs the test statistic T_{k}^{S} by replacing θ_{k} in (1) with ϵ_{k} . Similarly, one obtains the test statistic T^{NI} for testing $H_{0k}^{NI} : \theta_{k} \leq -\eta_{k}$ against $H_{1k}^{NI} : \theta_{k} > -\eta_{k}$ by replacing θ_{k} in (1) with $-\eta_{k}$. Define

$$\eta_k(\theta_k) = \frac{\eta_k + \theta_k}{\hat{\sigma}_k} \quad \text{and} \quad c_k = \frac{\epsilon_k + \eta_k}{\hat{\sigma}_k} \quad \frac{\epsilon_k + \eta_k}{1/n_1 + 1/n_2}$$

for k = 1, ..., m. Then the test statistics T_k^{NI} can be expressed in terms of T_k and $\eta'(\theta_k)$

$$T_k^{NI} = T_k + \eta'_k(\theta_k) \tag{2}$$

and T_k^{S} in terms of T_k^{NI} and c_k

$$T_{k}^{S} = T_{k}^{NI} - c_{k},\tag{3}$$

 $k = 1, \ldots, m$. Under the null hypothesis H^{NI} , i.e., $\theta_k \leq -\eta_k$, one has $\eta'(\theta_k) \leq 0$. Hence the null hypothesis H^{NI}_{0k} is rejected if

$$T_k^{NI} = T_k > t_{d,a}.$$

and H_{0k}^{S} is rejected if

$$T_k > t_{d,a'} + c_k, \tag{5}$$

where $t_{d,a}$ is the 100(1 – α ')% percentage point of the t_d with α' being appropriately adjusted for multiple tests in order to control the overall Type I error probability at α .

Tamhane and Logan (2004) propose to test H_0^S against H_1^S and H_0^N against H_1^N separately, each at level α , and the overall Type I error for testing H_0 against H_1 is controlled at α . They develop a method to obtain sharper critical values for the UI-IU test using bootstrap algorithm in a stepwise manner. In the next section, we develop a unified approach for simultaneous tests of superiority and non-inferiority where critical values are obtained using expanded probability expression for the Type I error rate based on least favorable configurations of the combined superiority and non-inferiority null hypotheses.

3 A Unified Approach

We first present an improved upper bound of Type I error probability based on which the adjusted significance level α' and its corresponding critical values that control the overall Type I error rate are derived.

3.1 Type I error probability

With the rejection regions defined marginally for H_{0k}^{NI} and H_{0k}^{S} as in (2) and (3), the overall Type I error probability γ for testing H_0 against H_1 is hence given by

$$\gamma = P_0 \left\{ \bigcup_{k=1}^m (T_k > t_{d,a'} - \eta'_k(\theta_k) + c_k) \cap \bigcap_{k=1}^m (T_k > t_{d,a'} - \eta'_k(\theta_k)) \right\},$$
(6)

where $P_0\{\cdot\}$ denotes the probability under the null hypothesis H_0 . By the improved Bonferroni inequality of Worsley (1982), an upper bound of γ can be written as

$$\gamma \leq {}^{m} P_{0} \quad T_{k} > t_{d,a'} - \eta'(\theta_{k}) + c_{k} \cap \bigcap_{i=1}^{m/=k} (T_{i} > t_{d,a'} - \eta'(\theta_{i}))$$

$$- \sum_{k=1}^{k=1} P_{0} \left\{ (T_{k_{1}} > t_{d,a'} - \eta'_{k_{1}}(\theta_{k_{1}}) + c_{k_{1}}) \cap (T_{k} > t_{d,a'} - \eta'_{k}(\theta_{k}) + c_{k}) \right\}$$

$$\cap \bigcap_{j=1}^{m/=k_{1},k} (T_{j} > t_{d,a'} - \eta'(\theta_{j})) , \qquad (7)$$

רו

in which we use the fact that $T_k > t_{d,a'} - \eta'_k(\theta_k) + c_k$ implies $T_k > t_{d,a'} - \eta'_k(\theta_k)$. Denote the right-hand side of (7) by γ' . It is not immediately clear how γ' behaves in the domain of individual θ_k 's. The following lemma states the relationship of γ' with any single θ_k , a necessary condition which helps prove the main result presented in Theorem 1.

Lemma 1. Conditional on $\boldsymbol{\theta}^{(-k)} = \boldsymbol{\theta} \setminus \theta_k = \{\theta_1, \dots, \theta_m\} - \theta_k, \gamma' \text{ is an increasing function of } \theta_k.$

A proof of lemma 1 is provided in Appendix A.1.

Given that the right-hand side of (7) is an increasing function of θ_k , the maximum of the upper bound of γ can be obtained by condition (7) on the least favorable configuration of H_0 which, as Tamhane and Logan (2004) noted, is either $\bigcap_{k=1}^{m} (\theta_k = \epsilon_k)$ or $(\theta_k = -\eta_k) \cap$ $(\bigcap_{i=1}^{m \neq k} (\theta_i \to \infty))$. The following theorem provides explicit formulas for the determination of the critical value $t_{d,a'}$ and hence the adjusted significance level α' that maximize the upper bound of the Type I error probability under the least favorable configuration of the combined superiority and non-inferiority hypotheses. **Theorem 1.** Let $\gamma_1(\alpha)$ and $\gamma_2(\alpha)$ be defined as

$$\gamma_1(\alpha') = \prod_{k=1}^{m} P_0\{(T_k > t_{d,a'}) \cap (\cap_{i=1}^{m \neq k} (T_i > t_{d,a'} - c_k))\}$$
(8)

$$\gamma_2(\alpha') = \max_{1 \le k \le m} P_0\{T_k > t_{d,a'} + c_k\} + (m-1)P_0\{T_k > t_{d,a'}\}.$$
(9)

Then the overall Type I error rate (6) is controlled at α if α' is chosen such that

$$\max \gamma_1(\alpha'), \gamma_2(\alpha') \leq \alpha.$$
(10)

A proof of Theorem 1 can be found in Appendix A.2.

The result in (10) provides the basis of finding the significance level α' that is appropriately adjusted for multiple tests such that the overall Type I error is controlled at α . When the T_k 's are exchangeable, that is, their probability distribution functions are symmetric in their arguments (e.g., $t_{d,a'}$, $\rho_{k_1k_2}$ and c_k), the quantities $\gamma_1(\alpha')$ in (8) and $\gamma_2(\alpha')$ (9) reduce to

$$\gamma_1(\alpha') = m P_0\{(T_1 > t_{d,a'}) \cap (\cap_{i=2}^m (T_i > t_{d,a'} - c))\},\tag{11}$$

$$\gamma_2(\alpha') = P_0\{T_1 > t_{d,a'} + c\} + (m-1)P\{T_1 > t_{d,a'}\}$$
(12)

with $c = c_1 = ... = c_m$.

3.2 Critical value $t_{d,a'}$

The determination of $t_{d,a'}$ or α' is the key for the simultaneous tests of superiority and non-inferiority hypotheses. While the algorithm of searching for α' is readily available, further explorations of α' may help elucidate its relationship with data structure and the pre-specified superiority and non-inferiority effect margins.

In order to determine α' and hence $t_{d,a'}$ that satisfies (10), first note that given the input m, $\rho_{k_1k_2}$, and d, both the error probabilities $\gamma_1(\alpha')$ and $\gamma_2(\alpha')$ are increasing functions of

 α' . In addition,

$$\gamma_1(\alpha') = mP_0\{ \bigcap_{k=1}^m (T_k > t_{d,a'}) \}$$

$$\leq \gamma_2(\alpha') = mP_0\{T_k > t_{d,a'}\}$$
(13)

as $c_k \rightarrow 0$ for all *k*'s and

$$\gamma_{1}(\alpha') = \prod_{k=1}^{m} P_{0}\{T_{k} > t_{d,a'}\}$$

$$\geq \gamma_{2}(\alpha') = (m-1)P_{0}\{T_{k} > t_{d,a'}\}$$
(14)

as $c_k \to \infty$ for all k's. Also note that $\alpha' = \alpha$ under certain extreme cases such as perfect correlation among all endpoints. Hence, the largest and smallest possible values of α' are α and α/m , respectively, with the later being the Bonferroni-adjusted significance level for each test.

To search for α' , the algorithm of bisection method of Gentle (2009, pp.246-248) is adopted. First let $\alpha'_{l(0)} = \alpha/m$ and $\alpha'_{u(0)} = \alpha$. After choosing α (say, $\alpha = 0.05$ or 0.025 for one-sided) and the precision $\xi \ge 0$ (say, $\xi = 10^{-5}$), one follows the steps described below to find an appropriate α' value that satisfies (10):

- 1. Set s = 0 and calculate $\alpha'_{(0)} = \alpha'_{l(0)} + \alpha'_{u(0)}$ /2;
- 2. Calculate $\Delta_{(0)} = \alpha'_{u(0)} \max \gamma_1(\alpha'_{(0)}), \gamma_2(\alpha'_{(0)})$. If $0 < \Delta_{(0)} \le \xi$ then stop and return $\alpha'_{(0)}$ as the solution of α' ; otherwise let $\alpha'_{l(1)} = \alpha'_{(0)}$ and $\alpha'_{u(1)} = \alpha'_{u(0)}$;
- 3. Calculate $\alpha'_{(1)} = \alpha'_{l(1)} + \alpha'_{u(1)}$ /2 and $\Delta_{(1)} = \alpha'_{u(1)} \max \gamma_1(\alpha'_{(1)}), \gamma_2(\alpha'_{(1)})$. If $\Delta_{(1)} \leq \zeta$, then stop and return $\alpha'_{(1)}$ as the solution of α' .
- 4. In general, at step s > 1 if $0 < \Delta_{(s)} \le \zeta$ then stop and return $\alpha'_{(s)}$ as the solution of $\alpha'_{(s)}$; otherwise let $\alpha'_{l(s)} = \alpha'_{(s-1)}$ and $\alpha'_{u(s)} = \alpha'_{u(s-1)}$;
- 5. Calculate $\alpha'_{(s)} = \text{and } \Delta_{(s)} = \alpha'_{u(s)} \max[\gamma_1(\alpha'_{(s)}), \gamma_2(\alpha'_{(s)})]$ and compare $\Delta_{(s)}$ with ξ and return to Step 4.

The computation of the error probabilities (8) and (9) requires the correlation matrix or partial correlation coefficients $\rho_{k_1k_2}$ of the test statistics. While one can always plug in the

estimates of the $\rho_{k_1k_2}$'s in the formula, an alternative yet simple approach when the $\rho_{k_1k_2}$'s are approximately equal is to estimate the mean correlation coefficient $\rho_{k_1k_2}$ by the method of Armitage and Parmar (1986)

$$\rho_{0} = \frac{2^{m-1} m}{(m-1)} |\rho_{ij}| + \frac{4^{m-1} m}{(|\rho_{ij}| - \frac{2^{m-1} m}{(i-1)}|\rho_{ij}|} + \frac{i=1}{m(m-1)} (|\rho_{ij}| - \frac{2^{m-1} m}{(i-1)}|\rho_{ij}|)^{2}}{m(m-1)}$$
(15)

and then use ρ_0 as the common partial correlation coefficient in (8) and (9) or (11) and (12) to obtain the error probabilities.

Given the number of endpoints *m*, common partial correlation coefficient ρ_0 , degrees of freedom *d*, and the common combined standardized margins *c* for superiority and non-inferiority, one can directly calculate the critical values $t_{d,a'}$ using the above bisection method. Figure 1 shows how the the critical values $t_{d,a'}$ change over the domain of combined standardized margin *c* from 0 to 5 (exchangeable case) for m = (2, 3), $\rho = (0, 0.5)$, d = (10, 50, 200). The behavior of $t_{d,a'}$ can be summarized as follows:

- (a) There is no monotonic trend in critical value $t_{d,a'}$ over effect margin. As *c* increases, $t_{d,a'}$ decreases initially, then reaches the lowest point at certain *c* value after which it starts increasing. This is because the adjusted α' is determined by γ_1 when *c* is large as implied in (14) and by γ_2 when *c* is small as indicated in (13). The turning point of *c* depends on *m*, ρ and *d*.
- (b) Given the effect margin c, the critical value $t_{d,a'}$ increases with m and ρ .
- (c) The impact of degree of freedom d on $t_{d,a}$ becomes smaller for sufficiently larger d values.

Given a critical value $t_{d,a'}$, the adjusted α' can be calculated conversely. Table 1 shows the adjusted α' values for selected combinations of ρ , c and d for m = 2, 3. The key message for Table 1 can be summarized as follows: (i) As the common effect margin c increases, the adjusted α' increases and then decreases, following the inverse pattern of $t_{d,a'}$ over the same range of c value, (ii) when c = 0 or c is large enough, α' approaches α/m regardless of ρ or d, which can be explained by (13) and (14), and (iii) the adjusted α' decreases as mand/or ρ increases.



Figure 1: Critical values $t_{d,a'}$ as a function of the number of endpoints *m*, common correlation coefficient ρ , degrees of freedom *d* and a common effect margin *c*.

Once α' and hence $t_{d,a'}$ are determined, one can easily calculate the exact $(1 - \alpha)$ % simultaneous one-sided confidence intervals $[L_1, \infty) \times \ldots \times [L_k, \infty) \times \ldots \times [L_K, \infty)$, where L_k is defined as

$$L_k = \hat{\theta}_k - t_{d,a} \cdot \hat{\sigma}_k \quad 1 / n_1 + n_2$$

		Degrees of freedom d							
т	ρ	С	10	20	30	40	50	100	200
2	0.0	0.0	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250
		0.5	0.0350	0.0366	0.0372	0.0375	0.0377	0.0380	0.0382
		1.0	0.0423	0.0443	0.0450	0.0454	0.0456	0.0459	0.0461
		2.0	0.0460	0.0437	0.0429	0.0425	0.0423	0.0418	0.0416
		3.0	0.0327	0.0307	0.0301	0.0298	0.0296	0.0292	0.0291
		4.0	0.0274	0.0263	0.0260	0.0259	0.0258	0.0256	0.0256
		5.0	0.0257	0.0252	0.0251	0.0251	0.0251	0.0250	0.0250
	0.5	0.0	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250
		0.5	0.0350	0.0366	0.0372	0.0375	0.0377	0.0380	0.0382
		1.0	0.0411	0.0401	0.0398	0.0396	0.0395	0.0392	0.0391
		2.0	0.0293	0.0282	0.0279	0.0277	0.0276	0.0274	0.0273
		3.0	0.0260	0.0255	0.0253	0.0253	0.0253	0.0252	0.0252
		4.0	0.0252	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250
		5.0	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250	0.0250
3	0.0	0.0	0.0167	0.0167	0.0167	0.0167	0.0167	0.0167	0.0167
		0.5	0.0206	0.0213	0.0215	0.0216	0.0217	0.0219	0.0219
		1.0	0.0229	0.0236	0.0239	0.0240	0.0240	0.0241	0.0242
		2.0	0.0246	0.0249	0.0249	0.0249	0.0249	0.0250	0.0250
		3.0	0.0249	0.0250	0.0250	0.0248	0.0245	0.0240	0.0237
		4.0	0.0211	0.0191	0.0186	0.0183	0.0182	0.0179	0.0178
		5.0	0.0180	0.0171	0.0170	0.0169	0.0168	0.0168	0.0168
	0.5	0.0	0.0167	0.0167	0.0167	0.0167	0.0167	0.0167	0.0167
		0.5	0.0206	0.0213	0.0215	0.0216	0.0217	0.0219	0.0219
		1.0	0.0229	0.0236	0.0239	0.0240	0.0240	0.0241	0.0242
		2.0	0.0230	0.0215	0.0210	0.0208	0.0206	0.0203	0.0201
		3.0	0.0183	0.0175	0.0172	0.0172	0.0171	0.0170	0.0170
		4.0	0.0170	0.0168	0.0167	0.0167	0.0167	0.0167	0.0167
		5.0	0.0167	0.0167	0.0167	0.0167	0.0167	0.0167	0.0167

Table 1: Adjusted α' values for m = 2, 3 and various choices of ρ , c and d

for a two-sample problem with estimated mean treatment effect $\hat{\theta}_k$, pooled standard deviation $\hat{\sigma}_k$ and sample sizes n_1 and n_2 for respective groups.

4 Type I error probability when p = r

Suppose that a clinical trial is considered positive if and only if superiority is demonstrated on at least p out of the m endpoints and noninferiority on the rest m - p endpoints. Then, the type I error probability of rejecting at least p out of $m H^S$'s and the rest $m - p H^{NI}$'s ok is given by

$$\gamma_{p} = P_{0} \{ \bigcup_{\substack{\nu=p \\ \nu=p}}^{m} (T_{k_{i}} > t_{d,a'} - \eta'_{k_{i}}(\theta_{k_{j}}) + c_{k_{j}}) \\ \cap \bigcap_{j=1}^{m \neq k_{1}, \dots, k_{\nu}} T_{k_{j}} > t_{d,a'} - \eta'_{k_{j}}(\theta_{k_{j}}) \} \}.$$
(16)

Define the usual Bonferroni summands

$$S_{\nu,m} = \sum_{1 \le k_1 < \dots < k_{\nu} \le m} P_0 \left\{ \bigcap_{i=1}^{\nu} (T_{k_i} > t_{d,a'} - \eta'_{k_i}(\theta_{k_i}) + c_{k_i} \right. \\ \left. \bigcap_{j=1}^{m \not = k_1, \dots, k_{\nu}} T_{k_j} > t_{d,a'} - \eta'_{k_j}(\theta_{k_j}) \right\}$$
(17)

with the summation taken over all subscripts satisfying $1 \le k_1 < \ldots < k_\nu \le m$. Then, the type I error probability (16) can be written as

$$\gamma_p = \prod_{\nu=p}^{m} (-1)^{\nu-p} \quad \begin{array}{c} \nu - 1 \\ p - 1 \end{array} S_{\nu,m}, \tag{18}$$

see, e.g., Feller (1968, p.109). A sharper upper bound on γ_p , due to Hoppe and Seneta (1990), is given by

$$\gamma_{p} \leq S_{p,m} - P_{0} \{ (T_{k} > t_{d,a'} - \eta'_{k}(\theta_{k}) + c_{k} - \eta'_{k} - \eta'_{k}(\theta_{k}) + c_{k} - \eta'_{k} - \eta'_{k} - \eta'_{k}(\theta_{k}) + c_{k} - \eta'_{k} - \eta'_$$

where the summation is taken over all $k \in \{k_1, ..., k_\nu\}$ and $k \le k_\nu - 1$. Note that per the definition of $S_{\nu,m}$ in (17), the right-hand side of (19) can also be written as

$$\gamma_{p} \leq P_{0} \{ (t_{d,a'} - \eta_{k}'(\theta_{k}) < T_{k} < t_{d,a'} - \eta_{k}'(\theta_{k}) + c_{k}$$

$$\cap \bigcap_{i=1}^{\nu} T_{k} > t_{d,a'} - \eta_{k}'(\theta_{k}) + c_{k} \cap \bigcap_{j=1}^{m} t_{1,...,k_{\nu},k} T_{k} > t_{d,a'} - \eta_{k_{j}}'(\theta_{k_{j}})$$

$$(20)$$

which is clearly increasing in $\{\eta'_{k_i}(\theta_{k_i}): 1 \le k_1 < \ldots < k_v \le m\}$ for all $k \in \{k_1, \ldots, k_v\}$.

Theorem 2. Let $\gamma_1(\alpha)$ and $\gamma_2(\alpha)$ be defined as

$$\gamma_1(\alpha_p) = \Pr\{\bigcap_{i=1}^p (T_{k_i} > t_{d,a'}) \cap (\bigcap_{i=1}^{m \neq k_1, \dots, k_p} (T_i > t_{d,a'} - c_k))\}$$
(21)

$$\gamma(a') = {m \atop 2 \ p} \max_{\substack{p \ 1 \le k \le m}} P\{T > t \ a, a' + c\} + {m \atop k, a'} P\{T > t \ a, a' + c\} + {m \atop m - p} P\{T > t \ a, a'\}.$$
(22)

Then the Type I error rate (16) is controlled at α if α' is chosen such that

$$\max \gamma_1(\alpha'), \gamma_2(\alpha') \leq \alpha.$$
(23)

Proof: It follows the proof of Theorem **??** and the rejection probability equation (16).

When the test statistics T_k 's are exchangeable with respect to their probability distri-

butional functions, the quantities $\gamma_1(\alpha'_p)$ in (21) and $\gamma_2(\alpha'_p)$ in (22) reduce to

$$y_{2}(\alpha'_{p}) = \frac{m}{p} P \{ T_{i} > t_{i} \quad d, a' + c + \frac{m}{m-p} P_{0} \{ T_{i} > t_{d,a'} \} .$$
(25)

5 Simulations

Simulations are performed to compare the overall Type I error rate and power of our proposed approach (abbreviated as CCZQ hereafter) with three existing methods whose algorithms are briefly described below.

Tamhane and Logan (2004)'s UI-IU test (referred to as TL hereafter) uses bootstrap algorithm to obtain sharper critical values in a stepwise manner. Specifically, the critical values d_3 and d_4 are solutions in the probability equation

$$P_{0} \quad \min_{1 \le k \le m} (T_{k} + c_{k}) > d_{3} \text{ and } \max_{1 \le k \le m} T_{k} > d_{4} = \alpha$$
(26)

where d_3 is set to equal $t_{d,a}$ and T_1, \ldots, T_m have the multivariate *t*-distribution. In Bloch et al. (2001)'s bootstrap-based method (referred to as BLT hereafter), the superiority null hypothesis H_0^S is tested using one-sided Hotelling T^2 test statistic which is modified to allow for unequal covariance matrices, and the non-inferiority null hypothesis H_0^{NI} is tested

using the IU test with rejection region given by $\min_{1 \le k \le m} t_k^{NI} > t_{d,a}$. The superiority and non-inferiority null hypothesis H_0 is rejected if

$$T^2 \times I \quad \min_{1 \le k \le m} t_k^{NI} > t_{d,a} > d_1, \tag{27}$$

where *I* denotes an indicator function, $d_1 > 0$ is a critical value that is determined by the Type I error probability. Perlman and Wu (2004) (referred to as PW hereafter) replace the Hotelling T^2 statistic in Bloch et al. (2001) by the multivariate one-sided likelihood ratio test statistic derived by Perlman (1969), and test H^S_0 and H_0^{NI} separately, each at level α , with the latter using the IU test. The test statistic for testing H^S , denoted by U^2 , is the difference between the observed vector $\bar{x}_1 - \bar{x}_2$ and its projection on to the non-positive orthant $O^- = \{\theta | \theta_k \le 0 \text{ for all } k\}$. Then H_0 is rejected if $U^2 > d_2$ and $\min_{1 \le k \le m} t^{NI}_k > t_{d,a}$, where d_2 is the solution to

$$\frac{1}{2}P \quad \frac{\chi^2_{m-1}}{\chi^2_{n_1+n_2-m}} > d_2 \quad + \frac{1}{2}P \quad \frac{\zeta^2_{m}}{\chi^2_{n_1+n_2-m-1}} > d_2 = \alpha.$$
(28)

We consider simulation settings that are similar to those in Logan and Tamhane (2008), that is, two-arm studies with a sample size $n_1 = n_2 = 100$, m = 2 endpoints, correlation coefficient $\rho = (0, 0.5)$ and the combined common standardized superiority and non-inferiority effect margins c = (0.2, 0.33, 0.5). All results are based on 10,000 simulations. Table 2 presents the overall Type I error rates which are controlled at a pre-defined level $\alpha = 0.05$ for all the methods in comparison (except for TL method with $\rho = 0.5$ and c = 0.33 for which the estimated Type I error rate = 0.051 that is considered within the simulation error). It is noted that the estimates of Type I error rates for our proposed approach are closest to the pre-defined nominal level 0.05 among all the methods in comparison, regardless of the correlation coefficient ρ and the common standardized superiority and non-inferiority effect margins c.

Simulations for power comparisons are performed using the same simulation setting as in the Type I error simulation with the following pairs of treatment effects on the two endpoints: $(\theta_1, \theta_2) = (0.4, 0)$, (0.66, 0), (0.4, 0.2) and (0.33, 0.33). Table 3 presents the results of power simulation for our approach and the three existing methods. Obviously, our unified approach outperforms all other three methods in terms of power for all scenarios

ρ	С	(θ_1, θ_2)	CCZQ	TL	PW	BLT
0	0.2	(0,0)	0.050	0.016	0.022	0.023
	0.33	(0,0)	0.050	0.031	0.032	0.033
	0.5	(0,0)	0.048	0.044	0.042	0.032
0.5	0.2	(0,0)	0.048	0.034	0.037	0.039
	0.33	(0,0)	0.050	0.051	0.049	0.043
	0.5	(0,0)	0.050	0.050	0.050	0.044

Table 2: Simulated Type I error probabilities of our proposed approach and three existing methods with pre-defined $\alpha = 0.05$

under consideration. In fact, after determining α' and hence $t_{d,a'}$ from (10), the power for our proposed approach can be directly calculated using the formula

Power =
$$P_1 \{ \cap_{k=1}^m (T_k > t_{d,a'} - \eta' (\theta^1)) \}$$

- $P_1 \{ (\cap_{k=1}^m (t_{d,a'} - \eta' (\theta^1)) < T_k \le t_{d,a'} - \eta' (\theta^1) + c_k) \}$ (29)

where $\eta'_k(\theta^1_k)$ is as defined in Section 2 with θ_k being replaced by θ^1_k an assumed value of θ_k under the alternative hypothesis for which the power is calculated. Equation (29) can also be used to determine the minimum sample size for which a desired power can be achieved.

6 Examples

Two examples are provided below to illustrate the use of the proposed approach, one with two primary endpoints and the other with four primary endpoints. These two examples are also discussed in Logan and Tamhane (2008).

6.1 Example 1

Röhmel et al. (2006) illustrate an example in a confirmatory clinical trial comparing a treatment with a placebo control (note that in practice an active control should be used to demonstrate non-inferiority of the new treatment over the active control which should retain some therapeutic effect than a placebo control). The trial randomized $n_1 = 442$ patients to the treatment group and $n_2 = 211$ patients to the control group. Two primary endpoints taken from each patient were assumed to follow approximately bivariate normal

ρ	η	(θ_1, θ_2)	CCZQ	TL	PW	BLT
0	0.2	(0.4,0)	0.269	0.214	0.227	0.239
		(0.66,0)	0.319	0.306	0.304	0.291
		(0.4,0.2)	0.737	0.630	0.681	0.696
		(0.33,0.33)	0.851	0.742	0.810	0.817
	0.3	(0.4,0)	0.585	0.466	0.468	0.433
		(0.66,0)	0.689	0.640	0.644	0.645
		(0.4, 0.2)	0.869	0.746	0.796	0.790
		(0.33,0.33)	0.901	0.778	0.842	0.844
	0.5	(0.4,0)	0.823	0.683	0.670	0.489
		(0.66,0)	0.957	0.932	0.929	0.862
		(0.4,0.2)	0.904	0.770	0.812	0.798
		(0.33,0.33)	0.915	0.777	0.845	0.849
0.5	0.2	(0.4,0)	0.305	0.268	0.266	0.255
		(0.66,0)	0.320	0.304	0.301	0.295
		(0.4,0.2)	0.740	0.645	0.650	0.642
		(0.33,0.33)	0.808	0.701	0.723	0.743
	0.3	(0.4,0)	0.629	0.535	0.529	0.356
		(0.66,0)	0.690	0.650	0.647	0.611
		(0.4, 0.2)	0.842	0.734	0.738	0.683
		(0.33,0.33)	0.835	0.706	0.725	0.752
	0.5	(0.4,0)	0.832	0.710	0.690	0.364
		(0.66,0)	0.958	0.938	0.932	0.755
		(0.4,0.2)	0.866	0.740	0.744	0.689
		(0.33,0.33)	0.850	0.719	0.735	0.746

Table 3: Simulated powers of our proposed approach and three existing methods with $\epsilon = 0$, and $\alpha = 0.05$

distribution with low values of the endpoints indicating beneficial effects. The summary statistics of the endpoints are as follows

$$\bar{x}_{1t} \sim N \square \frac{13.269}{22.796} , \square \frac{78.60082}{36.12524} \square \square,$$

$$\bar{x}_{2t} \sim N \square \frac{15.322}{23.512} , \square \frac{100.13374}{53.62950} \square \square,$$

where \bar{x}_{1t} and \bar{x}_{2t} denote respectively the sample means of the first and second endpoints for treatment group, and \bar{x}_{1c} and \bar{x}_{2c} the sample means of the first and second endpoints

for the control group. Röhmel et al. (2006) apply Läuter (1996)'s standard sum (SS) test for simultaneously testing superiority on at least one endpoint with superiority margins $\epsilon_1 = \epsilon_2 = 0$ and non-inferiority on both endpoints with non-inferiority margins $\eta_1 = 1$ and η_2 = 2. They obtain the global Läuter's SS test statistic 2.0416 which exceeds the critical value 1.9636 at one-sided 0.025 significance level, leading to the rejection of the superiority null hypothesis. They then compare the upper limit of the two-sided 95% confidence interval on the mean difference of each endpoint to its corresponding non-inferiority margin and conclude that the treatment is non-inferior over the control on both endpoints, which, together with the superiority test, leads to the conclusion that the trial successfully meets its objective. Logan and Tamhane (2008) also use this example data in their stepwise testing procedure in which they first calculate the t test statistics $t_1^{NI} = 3.945$ and $t_2^{NI} = 2.990$ for non-inferiority and compare these t statistics with the critical value 1.96, which leads to the rejection of non-inferiority hypotheses. They then apply a global test for testing superiority null hypothesis by comparing the maximum superiority test statistic $t^{S}_{max} = 2.653$ to the critical value 2.114 (obtained from bootstrap accounting for rejection of non-inferiority null hypotheses) or 2.220 (the upper 0.0215 percentile of standard normal distribution that does not take into account the rejection of non-inferiority null hypotheses) and conclude that the treatment is superior over the control on the fist endpoint.

We now apply our method to the above data by first calculating the standard *t* test statistics $t_1 = (15.322 \ 13.269)/(100.13374/211 + 78.60082/442)^{\frac{1}{2}} = 2.5418$ and $t_2 = (23.512-22.796)/(130.84153/211+111.65005/442)^{\frac{1}{2}} = 0.7664$, with correlation coefficient $\rho = (36.12524+53.6295)/[(78.60082+100.13374)(111.65005+130.84153)^{\frac{1}{2}} = 0.4311$. The standardized non-inferiority margins are $c_1 = 1/(78.60082/442+100.13374/211)^{\frac{1}{2}} = 1.2380$ and $c_2 = 2/(111.65005/442+130.84153/211)^{\frac{1}{2}} = 2.1409$. Plugging these numerical values into (8) and (9), we obtain $\alpha' = 0.0243$ from (10) which controls the overall Type I error rate at $\alpha = 0.025$, and hence have $t_{651,0.0243} = 1.9758$. Since $t_1 > 1.9758$ and $t_2 + c_2 > 1.9758$, we conclude that the treatment is superior over the control on the first endpoint and non-inferior on the second endpoint. The exact 97.5% simultaneous one-sided confidence intervals on

the mean difference of treatment effects on both endpoints are given by

$$[15.322 - 13.269 - t_{651,0.0243}(100.13374/211 + 78.60082/442)^{\frac{1}{2}}, \infty) \times [23.512 - 22.796 - t_{651,0.0243}(130.84153/211 + 111.65005/442)^{\frac{1}{2}}, \infty)$$

which reduces to $[0.4571, \infty) \times [-1.1298, \infty)$.

6.2 Example 2

Zhang et al. (1997) present a randomized clinical trial comparing a new drug ($n_1 = 34$) with a control ($n_2 = 35$) in terms of efficacy and safety among asthmatic patients. The trial includes the following four primary endpoints

- 1. forced expiratory volume in 1 second (FEV₁), in liters;
- 2. Symptoms score (SS), 0-6 scale;
- 3. Peak expiratory flow rate (PEFR), in liters per minute;
- 4. Additional medication use (AMU), i.e., agonist use, in puffs per day.

Sample means by group and pooled standard deviations for the four endpoints are given in Table 4. The estimated partial correlation coefficients $\rho_{k_1k_2}$ are presented in Table 5.

Group	Statistics	FEV ₁	SS	PEFR	AMU
Test drug	$ar{x}_{kt}$	14.0	0.86	16.5	0.49
Control	$ar{x}_{kc}$	5.7	0.34	1.6	0.15
Pooled	SD $(\hat{\sigma}_k)$	11.5	0.96	22.3	0.66

Table <u>4: The univariate analysis for the data of the asthma example</u>

Table 5:	The correlation among the four endpoints							
		PEV_1	SS	PEFR				
	SS	0.31						
	PEFR	0.25	0.42					
	AMU	0.24	0.67	0.43				

Before applying our approach to this data, we first calculate the common correlation coefficient $\rho_0 = 0.4298$ by equation (15) and then use formulas (8)-(10) to determine $\alpha' =$

0.01254 that controls the overall Type I error rate at $\alpha = 0.025$ (one-sided), which yields $t_{67,0.01254} = 2.2917$ (If we use the original correlation coefficients in Table (5), we obtain an adjust significance level $\alpha' = 0.01274$ and the corresponding critical value $t_{67,0.01274} = 2.2850$). Now we set a common superiority margin $\epsilon = 0$ and the standardized non-inferiority margins $c_k = 0.2\sigma_k$ for k = 1, 2, 3, 4, where σ_k denotes the pooled standard deviation for the *k*th endpoints (These non-inferiority margins are also used in Logan and Tamhane (2008)). Based on the summary statistics in Table (4), we obtain the *t* test statistics $t_1 = 2.9973$, $t_2 = 2.2495$, $t_3 = 2.7748$ and $t_4 = 2.1394$ for FEV₁, SS, PEFR and AMU, respectively. Using these *t* test statistics and the non-inferiority margins, we can conclude that the new drug is non-inferior over the control for all the four endpoints, and superior in FEV₁ and PEFR. The exact 97.5% simultaneous one-sided confidence intervals are therefore given by $[1.9539, \infty) \times [-0.0098, \infty) \times [2.59419, \infty) \times [-0.0242, \infty)$.

7 Discussions and Conclusions

We have proposed a unified approach to simultaneous testing of superiority and noninferiority hypotheses on multiple endpoints that are commonly seen in clinical trials. The proposed approach is based on the UI-IU test of Tamhane and Logan (2004) and the least favorable configurations of the superiority and non-inferiority null hypotheses, which leads to the solution of adjusted significance level α' for marginal tests that controls the overall Type I error rate at pre-defined α . Unlike existing methods which test superiority and noninferiority null hypotheses separately and control the Type I error rate each at α , our method provides a unified solution for testing superiority and non-inferiority hypotheses simultaneously using the derived significance level α' and its corresponding critical value that depend not only on the number of endpoints, correlation coefficients, and sample sizes, but also on the combined standardized superiority and non-inferiority margins. Simulation studies show that our proposed approach maintains a higher power than other available methods in scenarios under investigation. Since the adjusted significance level α' is derived that controls the overall Type I error rate at α , the $(1 - \alpha)\%$ simultaneous confidence intervals can be constructed, which is obviously another advantage of our approach.

The proposed method is based on general probability distributions and uses multivariate *t* distribution of continuous data as an illustration. Therefore, with appropriate modifica-

tion, the method can be extended to discrete outcomes and survival data. Some further improvements are under development to include sequential testing of superiority and non-inferiority hypotheses as well as simultaneous testing of superiority on at least $m_1 \ge 2$ endpoints and non-inferiority on the remaining $m - m_1$ endpoints.

A Appendix

A.1 Proof of lemma 1

Proof : Note that for any arbitrary k_1 , γ' can be written as

$$\gamma' = P_0 \left\{ \left[T_{k_1} > t_{d,\alpha'} - \eta'_{k_1}(\theta_{k_1}) + c_{k_1} \right] \cap \left[\bigcap_{i=1}^{m,\neq k_1} (T_i > t_{d,\alpha'} - \eta'_i(\theta_i)) \right] \right\} \\
+ \sum_{k=1}^{m,\neq k_1} \left[P_0 \left\{ \left[T_k > t_{d,\alpha'} - \eta'_k(\theta_k) + c_k \right] \cap \left[\bigcap_{i=1}^{m,\neq k} (T_i > t_{d,\alpha'} - \eta'_i(\theta_i)) \right] \right\} \\
- P_0 \left\{ (T_{k_1} > t_{d,\alpha'} - \eta'_{k_1}(\theta_{k_1}) + c_{k_1}) \cap (T_k > t_{d,\alpha'} - \eta'_k(\theta_k) + c_k) \\
\cap \left[\bigcap_{j=1}^{m,\neq k_1,k} (T_j > t_{d,\alpha'} - \eta'_j(\theta_j)) \right] \right\} \right] \\
= P_0 \left\{ \left[T_{k_1} > t_{d,\alpha'} - \eta'_{k_1}(\theta_{k_1}) + c_{k_1} \right] \cap \left[\bigcap_{i=1}^{m,\neq k_1} (T_i > t_{d,\alpha'} - \eta'_i(\theta_i)) \right] \right\} \\
+ \sum_{k=1}^{m,\neq k_1} P_0 \left\{ \left[T_{k_1} > t_{d,\alpha'} - \eta'_{k_1}(\theta_{k_1}) + c_{k_1} \right] \cap \left[t_{d,\alpha'} - \eta'_k(\theta_k) < T_k \right] \\
< t_{d,\alpha'} - \eta'_k(\theta_k) + c_k \right] \cap \left[\bigcap_{j=1}^{m,\neq k,k_1} (T_j > t_{d,\alpha'} - \eta'_j(\theta_j)) \right] \right\},$$
(30)

which clearly is a monotone increasing function of θ_{k_1} conditional on $\theta^{(k_1)}$, regardless of c_k for k = 1, ..., m.

A.2 Proof of Theorem 1

Proof: Recall that H_{0k}^{NI} implies H_{0k}^{S} and that the null hypothesis H_{0} : $\left(\bigcap_{k=1}^{m} H_{0k}^{S}\right) \cup \left(\bigcup_{k=1}^{m} H_{0k}^{NI}\right)$ can be decomposed into the following all possible individual components:

$$\begin{cases}
\bigcap_{k=1}^{m} H_{0k}^{S} = H_{0}^{S}, \\
H_{0}^{S(-k)} H_{0k}^{NI}, \quad k = 1, \dots, m, \\
H_{0}^{S(-k_{1}, -k_{2})} H_{0k_{1}}^{NI} H_{0k_{2}}^{NI}, \quad 1 \le k_{1} < k_{2} \le m, \\
\vdots \\
H_{0k}^{S} H_{0}^{NI(-k)}, \quad k = 1, \dots, m \\
H_{0k}^{NI}, \quad k = 1, \dots, m, \\
H_{0k_{1}}^{NI} H_{0k_{2}}^{NI}, \quad 1 \le k_{1} < k_{2} \le m, \\
\vdots \\
H_{01}^{NI} \dots H_{0m}^{NI} = H_{0}^{NI}
\end{cases}$$
(31)

where $H_0^{S(-k)} = \bigcap_{i=1}^{m,\neq k} H_{0i}^S$, $H_0^{S(-k_1,-k_2)} = \bigcap_{i=1}^{m,\neq k_1,k_2} H_{0i}^S$, and $H_0^{NI(-k)} = \bigcap_{i=1}^{m,\neq k} H_{0i}^{NI}$. Let $\gamma(H_{0i})$ be the upper bound of the Type I error probability under, i.e., the right-hand side of (7), under one of the null hypothesis configurations listed in (31), denoted by H_{0i} . As $\gamma(H_{0i})$ is monotone with respect to θ_k while conditioning on $\theta^{(-k)}$, one has the following

$$\gamma(\cap_{k=1}^{m} H_{0k}^{S}) \geq \gamma'(H_{0}^{S(-k)} H_{0k}^{NI}) \\
\geq \gamma(H_{0}^{S(-k_{1},-k_{2})} H_{0k_{1}}^{NI} H_{0k_{2}}^{NI}) \\
\geq \dots \\
\geq \gamma(H_{0k}^{S} H_{0}^{NI(-k)})$$
(32)

 and

$$\gamma(H_{0k}^{NI}) \geq \gamma(H_{0k_1}^{NI}H_{0k_2}^{NI})$$

$$\geq \dots$$

$$\geq \gamma(H_{01}^{NI}\dots H_{0m}^{NI}).$$
(33)

That is, the maximum of the upper bound of the Type I error rate is either $\gamma(\cap^m = H^S_{0k})$ or $\max_{1 \le k \le m} \gamma(H^N_{0k})$. Note that under $H^S = \cap^m H^S_{k=1}$, one has

$$\gamma(\bigcap_{k=1}^{m} H_{0k}^{S}) \leq \prod_{k=1}^{m} P_{0}\{(T_{k} > t_{d,a'}) \cap (\bigcap_{i=1}^{m, k} (T_{i} > t_{d,a'} - c_{i}))\} = \gamma_{1}(\alpha')$$
(34)

and under H_{0k}^{NI} one has

$$\gamma(H_{0k}^{NI}) \leq \max_{1 \leq k \leq m} P_0\{T_k > t_{d,a'} + c_k\} + (m-1)P_0\{T_k > t_{d,a'}\} = \gamma_2(\alpha').$$
(35)

Whether $\gamma_1(\alpha') \ge \gamma_2(\alpha')$ or $\gamma_1(\alpha') \le \gamma_2(\alpha')$ depends on the data structure (i.e., the number of endpoints *m*, partial correlation coefficient ρ_{k_1,k_2} and degree of freedom *d*) as well as the pre-defined effect margin c_k . If one controls $\max(\gamma_1, \gamma_2)$, then the Type I error rate is controlled. This completes the proof.

References

- Armitage, P. and M. Parmar (1986). Some approaches to the problem of multiplicity in clinical trials. In *Proceedings of the XIIIth International Biometric Conference*, Volume 1171, pp. 251–273.
- Berger, R. L. (1982). Multiparameter hypothesis testing and acceptance sampling. *Technometrics* 24 (4), 295–300.
- Bloch, D. A., T. L. Lai, Z. Su, and P. Tubert-Bitter (2007). A combined superiority and noninferiority approach to multiple endpoints in clinical trials. *Statistics in Medicine* 26 (6), 1193–1207.
- Bloch, D. A., T. L. Lai, and P. Tubert-Bitter (2001). One-sided tests in clinical trials with multiple endpoints. *Biometrics* 57 (4), 1039–1047.
- FDA (2016). Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment– Guidance for Industry. US Food and Drug Administration. Silver Spring, MD.

- Feller, W. (1968). *An introduction to probability theory and its applications: volume I*, Volume 3. John Wiley & Sons New York.
- Gentle, J. (2009). Computational Statistics. Springer, New York.
- Hochberg, Y. (1988). A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75, 800–802.
- Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 6, 65–70.
- Hoppe, F. M. and E. Seneta (1990). A bonferroni-type identity and permutation bounds. International Statistical Review/Revue Internationale de Statistique, 253–261.
- Läuter, J. (1996). Exact *t* and *F* tests for analyzing studies with multiple endpoints. *Biometrics* 52 (3), 964–970.
- Logan, B. R. and A. C. Tamhane (2008). Superiority inferences on individual endpoints following noninferiority testing in clinical trials. *Biometrical Journal 50* (5), 693–703.
- Perlman, M. D. (1969). One-sided testing problems in multivariate analysis. *The Annals of Mathematical Statistics* 40 (2), 549–567.
- Perlman, M. D. and L. Wu (2004). A note on one-sided tests with multiple endpoints. *Biometrics* 60 (1), 276–280.
- Röhmel, J., C. Gerlinger, N. Benda, and J. Läuter (2006). On testing simultaneously noninferiority in two multiple primary endpoints and superiority in at least one of them. *Biometrical journal* 48 (6), 916–933.
- Roy, S. N. (1953). On a heuristic method of test construction and its use in multivariate analysis. *The Annals of Mathematical Statistics* 24 (2),220–238.
- Tamhane, A. C. and B. R. Logan (2004). A superiority-equivalence approach to one-sided tests on multiple endpoints in clinical trials. *Biometrika* 91 (3), 715–727.
- Vellas, B., S. Andrieu, C. Sampaio, N. Coley, and G. Wilcock (2008). Endpoints for trials in alzheimer's disease: a european task force consensus. *The Lancet Neurology* 7 (5), 436–450.

- Worsley, K. (1982). An improved bonferroni inequality and applications. *Biometrika* 69(2), 297–302.
- Zhang, J., H. Quan, J. Ng, and M. E. Stepanavage (1997). Some statistical methods for multiple endpoints in clinical trials. *Controlled Clinical Trials* 18 (3), 204–221.